Company intelligence / Profile preview

TearSolutions, Inc.

Charlottesville, Virginia, United Statestearsolutions.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Completed Phase I/II clinical trial of Lacripep in primary Sjögren's Syndrome patients, showing statistically significant improvement in both sign (inferior corneal staining) and symptom (burning and stinging) at two weeks[5]. Currently preparing for Phase II clinical trial to evaluate safety and efficacy in the general DED population[5].

Therapeutic areas: OphthalmologyImmunology
Modalities: Peptide therapy
Industry: Biotech

Drug pipeline

1 asset

Lacripep

Beyond the preview

Go deeper on TearSolutions, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TearSolutions, Inc..

Explore the full profile